Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF)

Clinical Science

Volumn 116, Issue 10, 2009, Pages 781-789

  Pinto, Antonio ^a   Tuttolomondo, Antonino ^a   Casuccio, Alessandra ^a   Di Raimondo, Domenico ^a   Di Sciacca, Riccardo ^a   Arnao, Valentina ^a   Licata, Giuseppe ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Atrial fibrillation; Interleukin 6 (IL 6); Stroke; Tumour necrosis factor (TNF ); Von Willebrand factor (vWF)

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; PADGEM PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN TISSUE; HYPERTENSION; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STROKE;

AGED; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CHRONIC DISEASE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; STROKE;

EID: 67649252387     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20080372     Document Type: Article

References (25)

1. Kannel, B., Wolf, P. A., Benjamin, E. J. and Levy, D. (1998) Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am. J. Cardiol. 82 (Suppl. 8A), 2N-9N
2. Atrial Fibrillation Investigators (1998) Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1, 066 patients from 3 clinical trials. Arch. Intern. Med. 158, 1316-1320
3. Baruch, L., Gage, B. F., Horrow, J., Juul-Moller, S., Labovitz, A., Persson, M. and Zabalgoitia, M. (2007) Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? A comparison of seven stroke prediction schemes. Stroke 38, 2459-2463
4. Inoue, H., Nozawa, T., Okumura, K., Jong-Dae, L., Shimizu, A. and Yano, K. (2004) Prothrombotic activity is increased in patients with nonvalvular atrial fibrillation and risk factors for embolism. Chest 126, 687-692 (Pubitemid 39258018)
5. Lip, G. Y., Lip, P. L., Zarifis, J., Watson, R. D., Bareford, D., Lowe, G. D. and Beevers, D. G. (1996) Fibrin D-dimer and β-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation: effects of introducing ultra-low-dose warfarin and aspirin. Circulation 94, 425-431 (Pubitemid 26266127)
6. Lip, G. Y., Lowe, G. D., Rumley, A. and Dunn, F. G. (1996) Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Am. Heart J. 31, 724-730
7. Chung, M. K., Martin, D. O., Sprecher, D., Wazni, O., Kanderian, A., Carnes, C. A., Bauer, J. A., Tchou, P. J., Niebauer, M. J., Natale, A. and Van Wagoner, D. R. (2001) C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104, 2886-2891 (Pubitemid 33139098)
8. Frustaci, A., Chimenti, C., Bellocci, F., Morgante, E., Russo, M. A. and Maseri, A. (1997) Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96, 1180-1184 (Pubitemid 27344221)
9. Conway, D. S., Buggins, P., Hughes, E. and Lip, G. Y. (2004) Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am. Heart J. 148, 462-466
10. Lévy, S., Camm, A. J., Saksena, S., Aliot, E., Breithardt, G., Crijns, H., Davies, W., Kay, N., Prystowsky, E., Sutton, R. et al. (2003) International consensus on nomenclature and classification of atrial fibrillation; a collaborative project of theWorking Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Europace 5, 119-122 (Pubitemid 36372367)
11. Devereux, R. B. and Roman, M. J. (1995) Evaluation of cardiac and vascular structure and function by echocardiography and other non-invasive techniques. In Hypertension: Pathophysiology, Diagnosis and Management 2nd edn (Laragh, J. H. and Brenner, B. M., eds), pp. 281-289, Raven Press, New York
12. Expert Committee on the Diagnosis, Classification of Diabetes Mellitus (1998) Report of the Expert Commettee on the diagnosis and classification of diabetes mellitus. Diabetes Care 21 (Suppl. 1), S5-S19
13. Expert Committee on the Diagnosis, Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20, 183-197
14. Zanchetti, A., Chalmer, J. P., Arakawa, K., Gyarfas, I., Hamet, P., Hansson, L., Julius, S., MacMahon, S., Mancia, G. and Menard, J. (1993) The 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. Blood Press. 2, 86-100 (Pubitemid 23283623)
15. Drown, D. J. and Engler, M. M. (1994) New guidelines for blood cholesterol by the National Cholesterol Education Program (NCEP). Prog. Cardiovasc. Nurs. 9, 43-44
16. National Cholesterol Education Program Panel (1994) Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 89, 1333-1445
17. Task Force on Heart Failure of the European Society of Cardiology (1995) Guidelines for the diagnosis of heart failure. Eur. Heart J. 16, 741-751
18. Aho, K., Armussen, P., Hatano, S., Marquardsen, J., Smirnov, V. E. and Strasser, T. (1980) Cerebrovascular disease in the community: results of a WHO collaborative study. Bull. World Health Organ. 58, 113-130
19. Marcus, G. M., Whooley, M. A., Glidden, D. V., Pawlikowska, L., Zaroff, J. G. and Olgin, J. E. (2008) Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am. Heart J. 155, 303-309
20. Lip, G. Y., Lane, D., Van Walraven, C. and Hart, R. G. (2006) Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 37, 2294-2300 (Pubitemid 44337172)
21. Roldán, V., Marín, F., García-Herola, A. and Lip, G. Y. (2005) Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation. Thromb. Res. 116, 321-325
22. Kerr, R., Stirling, D. and Ludlam, C. A. (2001) Interleukin 6 and haemostasis. Br. J. Hematol. 115, 3-12
23. Baruch, L., Gage, B. F., Horrow, J., Juul-Moller, S., Labovitz, A., Persson, M. and Zabalgoitia, M. (2007) Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? A comparison of seven stroke prediction schemes. Stroke 38, 2459-2463
24. MacFadyen, R. J. (2006) Intraindividual temporal variance of biomarkers and the definition of individualized prognosis in cardiovascular patients. J. Hum. Hypertens. 20, 383-386
25. Evans, A., Perez, I., Yu, G. and Kalra, L. (2001) Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation. Stroke 32, 2828-2832 (Pubitemid 33134473)